Transdermal Estradiol Patches Noninferior to LHRH Agonists for Prostate Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, April 10, 2026 -- For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing hormone-releasing hormone (LHRH) agonists as androgen deprivation therapy, according to a study published online March 25 in the New England Journal of Medicine.

Ruth E. Langley, M.B., B.S., Ph.D., from University College London, and colleagues conducted a phase 3, noninferiority, randomized trial involving men with locally advanced prostate cancer who received tE2 patches (100 µg estradiol every 24 hours) or LHRH agonists.

A total of 1,360 patients at 75 U.K. centers were recruited between 2007 and 2022. The researchers found that the observed three-year metastasis-free survival was 87.1 and 85.9 percent with tE2 and LHRH agonists, respectively (hazard ratio [HR] for confirmed metastasis or death, 0.96; upper limit of the one-sided 95 percent confidence interval [CI], 1.11, which met the criterion for noninferiority). Castrate levels of testosterone (<1.7 nmol/L) were sustained during the first year after randomization in 85 percent in each group among patients continuing their assigned treatment. Observed five-year overall survival was 81.1 and 79.2 percent with tE2 and LHRH agonists, respectively (HR for death, 0.90; 95 percent CI, 0.75 to 1.07). Hot flashes occurred in 44 and 89 percent of patients who received tE2 and LHRH agonists, respectively, and gynecomastia occurred in 85 and 42 percent, respectively.

"We believe our findings should lead to men with locally advanced prostate cancer being able to choose which hormone therapy suits them best. For some men, for instance, hot flushes can be very debilitating, and so the patches could greatly increase their quality of life," Langley said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-11 01:45

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords